← Back to Analyst Consensus 
ZNTL Buy
Zentalis Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 16, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Jul 23, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Jul 17, 2026 | Mizuho | initiate | — → Outperform | — | 52% |
| Apr 10, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 27, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Nov 12, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $4 | 54% |
| Aug 7, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $5 | 54% |
| May 15, 2025 | Wedbush | reiterate | Neutral → Neutral | $4 | 58% |
| May 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 28, 2025 | Wedbush | reiterate | Neutral → Neutral | $4 | 58% |
| Mar 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Jan 30, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $6 | 54% |
| Jan 29, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Jan 28, 2025 | UBS | maintain | Neutral → Neutral | $2.2 | 54% |
| Nov 15, 2024 | Guggenheim | maintain | Buy → Buy | $8 | 52% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Sep 16, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $20 | 52% |
| Aug 12, 2024 | Wedbush | upgrade | Underperform → Neutral | $4 | 58% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Jun 20, 2024 | UBS | downgrade | Buy → Neutral | $5 | 54% |
| Jun 18, 2024 | Wells Fargo | downgrade | Overweight → Equal-Weight | $9 | 54% |
| Jun 18, 2024 | Stifel | maintain | Buy → Buy | $10 | 53% |
| Jun 18, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Jun 18, 2024 | Oppenheimer | maintain | Outperform → Outperform | $25 | 52% |
| Jun 18, 2024 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $8 | 54% |
| May 8, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| May 8, 2024 | Stifel | maintain | Buy → Buy | $32 | 53% |
| Feb 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $46 | 44% |
| Feb 28, 2024 | Wedbush | maintain | Neutral → Neutral | $15 | 58% |
| Nov 8, 2023 | Wedbush | downgrade | Outperform → Neutral | $12 | 58% |
| Nov 7, 2023 | Stifel | maintain | Buy → Buy | $36 | 53% |
| Nov 7, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $38 | 54% |
| Nov 7, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $46 | 44% |
| Aug 10, 2023 | Wells Fargo | maintain | Overweight → Overweight | $50 | 54% |
| Aug 10, 2023 | Wedbush | reiterate | Outperform → Outperform | $38 | 58% |
| Aug 10, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $55 | 44% |
| Jun 7, 2023 | Wedbush | reiterate | Outperform → Outperform | $38 | 58% |
| Jun 7, 2023 | Stifel | maintain | Buy → Buy | $50 | 53% |
| Jun 2, 2023 | Stifel | maintain | Buy → Buy | $45 | 53% |
| May 29, 2023 | Stifel | maintain | Buy → Buy | $45 | 53% |
| May 26, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $50 | 52% |
| May 26, 2023 | Wedbush | maintain | Outperform → Outperform | $38 | 58% |
| May 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $55 | 44% |
| May 23, 2023 | Stifel | maintain | Buy → Buy | $45 | 53% |
| May 19, 2023 | Jefferies | maintain | Buy → Buy | $70 | 52% |
| May 15, 2023 | Stifel | maintain | Buy → Buy | $45 | 53% |
| May 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $55 | 44% |
| May 11, 2023 | Oppenheimer | reiterate | Outperform → Outperform | $50 | 52% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days